EZEvgeniy G. Zotkin

Evgeniy G. Zotkin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Evgeniy G. Zotkin has a total of 232 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Autoimmune thyroiditis as a component of polyautoimmunity in patients with rheumatoid arthritis

    by S. Yu. Shkireeva, E. G. Zotkin, С. Ю. Шкиреева, Е. Г. Зоткин

    Over recent decades, a global increase in autoimmune diseases has been observed. The predisposition for a single patient to develop multiple autoimmune diseases, associated with the hyperproduction of autoantibodies of varying specificity, has been termed polyautoimmunity. The combination of three or more autoimmune diseases is defined as multiple autoimmune syndrome (MAS). The pathogenesis of MAS remains insufficiently studied. The literature widely discusses the role of common pathogenetic factors leading to the development of MAS, including infectious, environmental, and metabolic influences. Currently, more than 140 autoimmune diseases affecting various areas of clinical medicine have been described. The most common among all autoimmune pathologies is the combination of rheumatoid arthritis (RA) with autoimmune thyroid disease, which is considered by some authors as a variant of autoimmune polyglandular syndrome type 3D. At the same time, data on the frequency of various combinations of autoimmune diseases or the development of MAS in patients with RA remain limited. The study of clinical phenotypes of autoimmune pathology in patients with RA is relevant for a better understanding of the mechanisms of polyautoimmunity. The aim . To assess the frequency of autoimmune thyroid involvement in patients with rheumatoid arthritis, to study the clinical and immunological features of the rheumatoid arthritis course in the presence of autoimmune thyroiditis (AIT), and to determine the frequency of multiple autoimmune syndrome in patients with rheumatoid arthritis. Materials and methods . A retrospective analysis of 1,648 medical records of patients with RA hospitalized at the V.A. Nasonova Research Institute of Rheumatology between 2021 and 2025 was performed. Patients with autoimmune thyroiditis (n=72) were compared with a control group of patients with RA and nodular goiter (n=60). Demographic data, serological status, autoantibody profiles, comorbid autoimmune diseases and МАС were assessed. Results . Autoimmune thyroid disease was identified in 16.7% of patients with RA. The presence of AIT was associated with a significantly higher frequency of antinuclear antibody (ANA) positivity (ANA≥1:320; p=0.010), increasing the odds of ANA positivity by 4.76 times. Patients with RA and AIT more frequently exhibited additional autoimmune diseases, inadequate response to basic therapy, and fulfillment of difficult-to-treat RA criteria. Multiple autoimmune syndrome was diagnosed in 8.9% of patients. Conclusions. Autoimmune thyroiditis represents a major component of polyautoimmunity in rheumatoid arthritis and is associated with a more unfavorable disease course, emphasizing the need for comprehensive interdisciplinary management.

  • Open Access

    Differential diagnosis of cytopenia in diffuse toxic goiter: A look through the prism of multiple autoimmune syndrome

    by T. S. Panevin, E. G. Zotkin, T. С. Паневин, Е. Г. Зоткин

    Diffuse toxic goiter (Graves’ disease) is an organ-specific autoimmune disorder of the thyroid gland, most often causing hyperthyroidism in iodine-rich regions. Its development is caused by the production of thyroid-stimulating antibodies directed against thyroid-stimulating hormone receptors (TSH receptor antibodies). In addition to the classic symptoms of diffuse toxic goiter, patients with this disease may experience hematological manifestations such as anemia, leukopenia, and thrombocytopenia. Hematological abnormalities in Graves’ disease are relatively common, but their clinical significance increases significantly. In most cases, cytopenia is moderate and reversible. This condition may be associated with the direct effects of excess thyroid hormones associated with thyrotoxicosis syndrome, the use of antithyroid drugs, or the presence of comorbidities. In addition to hematological diseases, which are the cause of cytopenia, its presence can be caused by other autoimmune diseases, such as systemic lupus erythematosus, Sjögren’s syndrome, autoimmune gastritis, celiac disease, autoimmune hemolytic anemia, and others. One of the symptoms or diseases of these diseases may be a disruption in the production or an increase in the disorder of formed blood elements. The frequent combination of Graves’ disease with other autoimmune diseases in multiple autoimmune syndrome (MAS) or autoimmune polyglandular syndrome necessitates a differential diagnosis of cytopenia in Graves’ disease. A literature search was conducted in PubMed/MEDLINE, eLIBRARY.ru, Cochrane Library, and Google Scholar for the period from 1980 to 2026. A total of 128 publications were evaluated, of which 41 were included in the review.

  • Open Access

    Immunopathology of polymyalgia rheumatica: Links to clinical manifestations and prospects for targeted therapy

    by E. V. Arsenyev, B. S. Belov, E. G. Zotkin, Е. В. Арсеньев, Б. С. Белов, Е. Г. Зоткин

    Polymyalgia rheumatica (PMR) is one of the most common inflammatory rheumatic diseases affecting older adults. The aim of this review was to analyze current concepts of the immunopathogenesis of PMR and the possibilities of pathogenetic therapy for this disease. A literature search was conducted in the PubMed, Scopus, Web of Science, eLIBRARY.RU and Google Scholar databases using the following keywords: “polymyalgia rheumatica”, “immunopathogenesis”, “immunosenescence”, “methotrexate”, “biologic therapy”, “IL-6 inhibitors”, “IL-17 inhibitors”, “targeted therapy”, “tocilizumab”, “sarilumab”, “olokizumab”, “tofacitinib”, “baricitinib”, and their Russian-language equivalents. A total of 110 publications were initially identified. Following full-text assessment, 24 articles were excluded due to lack of relevance to the review topic, insufficient informativeness, or the absence of significant data regarding the immunopathogenesis and treatment of PMR. A total of 86 publications were included in the qualitative analysis, comprising randomized controlled trials, cohort studies, clinical observations, systematic reviews, and basic research studies. Twelve publications focusing on the immunopathology of PMR were used for preparation of the Introduction section. The analysis demonstrated that immunosenescence, activation of innate and adaptive immunity, disturbances in Tand B-cell immune responses, and dysregulation of the cytokine network, with a central role of interleukin-6, are key contributors to the pathogenesis of PMR. The most convincing evidence currently supports the use of interleukin-6 and interleukin-17 inhibitors, whose efficacy has been confirmed in randomized clinical trials. Expanding knowledge of the mechanisms underlying the disease contributes to the development of personalized treatment approaches for patients with PMR and to the optimization of long-term disease control.

  • Open Access

    Quality of life in men with rheumatoid arthritis and testosterone deficiency

    by T. S. Panevin, A. M. Lila, E. G. Zotkin, A. S. Potapova, S. I. Glukhova, E. A. Strebkova, M. V. Podryadnova, M. K. Kurbanmagomedov, Т. С. Паневин, А. М. Лила, et al.

    Introduction . Low testosterone levels are common in men with rheumatoid arthritis (RA). Patients with RA and hypogonadism have higher levels, reflecting systemic inflammation. Both RA and hypogonadism can negatively impact quality of life. Aim. To assess the impact of low testosterone levels on quality of life in men with RA. Materials and methods . A cross-sectional study of 73 men diagnosed with RA was conducted. All patients had their total blood testosterone levels measured and were administered the HAQ, EQ-5D, and HADS questionnaires. A cross-sectional comparison of quantitative and qualitative parameters was performed between normal and low (≤12.0 nmol/L) total blood testosterone levels. Results . Patients with hypogonadism and RA were characterized by lower quality of life indicators, which was reflected in the results of the HAQ questionnaires (1.59 ± 0.88 vs. 1.09 ± 0.87; p = 0.036), EQ-5D (0.52 [-0.01; 0.64] vs. 0.62 [0.52; 0.69]; p = 0.048), as well as the patient’s assessment of the general condition using VAS (70.0 [60.0; 80.0] vs. 60.0 [55.0; 70.0]; p = 0.039). The results of the HADS questionnaire were comparable in the studied subgroups. In the correlation analysis, the HAQ score correlated with RA activity according to DAS28CRP (r = 0.58; p < 0.001), ESR (ρ = 0.51; p < 0.001) and CRP (ρ = 0.55; p < 0.001), as well as the class of functional impairment (ρ = 0.26; p = 0.025), total testosterone (ρ = -0.3; p = 0.009) and hemoglobin (ρ = -0.48; p < 0.001). High RA activity (DAS28CRP ≥ 5.1), but not the presence of hypogonadism, as well as factors related to age and body weight, significantly increased the likelihood of having more negative results according to the HAQ questionnaire: OR 17.5; 95% CI 4.5–68.1 (p < 0.001) for HAQ ≥ 1.0 and OR 18.12; 95% CI 1.03–319.23 (p = 0.048) for HAQ ≥ 2.0. Conclusion. Patients with RA and hypogonadism have a lower quality of life, which is due to the influence of inflammatory activity.

  • Open Access

    Review of Clinical Guidelines «Sarcopenia in Elderly Patients»

    by O. N. Tkacheva, A. M. Lila, N. N. Zubareva, V. A. Tutelyan, Yu. V. Kotovskaya, N. K. Runikhina, A. V. Naumov, E. N. Dudinskaya, N. O. Khovasova, N. V. Sharashkina, et al.

    This review outlines the key points from the clinical guidelines «Sarcopenia in Elderly Patients», covering definition, epidemiology, clinical features, diagnostic approaches, and treatment strategies. The information is intended to help individuals manage patients aged 60 years or older with a focus on muscle health.

  • Open Access

    Analysis of clinical and laboratory parameters affecting testosterone dynamics in men with ankylosing spondylitis and psoriatic arthritis: Results of a pilot observational study

    by T. S. Panevin, T. V. Korotaeva, T. V. Dubinina, E. G. Zotkin, A. M. Lila, Yu. I. Korsakova, L. D. Vorobyeva, E. M. Agafonova, S. I. Glukhova, E. L. Nasonov, et al.

    Men with spondyloarthritis (SpA) are characterized by a high incidence of hypogonadism (low testosterone levels). Hypogonadism is associated with higher indicators of systemic inflammation and metabolic disorders. The aim – to compare the dynamics of spondyloarthritis activity with changes in total testosterone (TT) levels in men with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Materials and methods . Thirty-six men with AS and 47 men with PsA were included. All patients had their TT levels measured at baseline and during follow-up (on average, after 14.5 [12.8; 17.3] months for AS and 14.0 [9.5; 19.0] months for PsA). Subgroups were identified based on the presence/absence of decreased BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and DAPSA (Disease Activity in Psoriatic Arthritis) indices, as well as C-reactive protein (CRP) levels. A comparative assessment of quantitative and qualitative indicators reflecting the clinical features of AS and PsA was conducted at baseline and over time, as well as a correlation analysis between the studied quantitative indicators over time. Results. An inverse correlation was found between changes in testosterone levels and CRP (ρ=–0.4; p=0.015) in patients with AS. In PsA, no significant correlations were found between changes in TT levels and changes in indicators reflecting activity. In patients with AS, with decreased BASDAI activity, no significant changes in TT levels were observed. At the same time, a decrease in CRP from 9.6 [2.7; 33.9] to 1.9 [0.65; 8.5] mg/L (pConclusion. In patients with AS, a decrease in CRP during treatment is accompanied by an increase in TT levels.

  • Open Access

    Hepcidin, but not erythropoietin, levels are associated with decreased testosterone in men with immune-mediated inflammatory rheumatic diseases and anemia

    by Taras S. Panevin, Evgeniy G. Zotkin, Aleksander M. Lila, Elena A. Galushko, Anna S. Semashko, Svetlana I. Glukhova, Mikhail E. Diatroptov

    Background. Anemia and decreased testosterone levels in men are common comorbidities in immune-mediated inflammatory rheumatic diseases (IIRDs). Aim. To evaluate the relationship between total testosterone (TT) and hepcidin and erythropoietin levels in men with IIRDs and anemia. Materials and methods. A cross-sectional study included 136 men with IIRDs (66 patients with rheumatoid arthritis – RA, 44 with ankylosing spondylitis – AS, 26 with psoriatic arthritis – PsA) and anemia. A correlation analysis was performed for all quantitative parameters with TT, hepcidin, and erythropoietin levels, as well as a comparative subgroup analysis between patients with normal and reduced (≤12.0 nmol/L) TT. Results. In RA, AS and PsA and anemia, the subgroup with reduced TT was characterized by comparable levels of hemoglobin and erythropoietin compared to patients without androgen deficiency. The hepcidin level in RA patients with testosterone deficiency was significantly higher (38.0 [31.8; 39.1] ng/ml versus 21.5 [7.8; 30.5] ng/ml; p0.001) in RA patients. Among patients with AS, the subgroup with reduced TT was characterized by comparable levels of hepcidin (29.2 [6.5; 34.1] ng/ml versus 31.3 [27.2; 34.9] ng/ml; p=0.3). Among patients with PsA, the subgroup with reduced TT levels was characterized by higher hepcidin levels in testosterone deficiency (37.0 [29.9; 38.7] ng/ml vs. 25.8 [4.6; 33.0] ng/ml; p=0.009). Conclusion. The obtained results indicate no relationship between TT levels and erythropoietin in patients with RA, AS, and PsA and concomitant anemia, while reduced TT levels were associated with increased hepcidin levels in RA and PsA, and are most likely due to high IIRD activity.

  • Open Access

    Current anti-inflammatory therapy for rheumatoid arthritis: efficacy issues (based on EULAR 2025 materials)

    by Yu. A. Olyunin, B. S. Belov, E. G. Zotkin, A. M. Lila

    In modern rheumatology, the problem of rheumatoid arthritis (RA) treatment remains highly relevant. This is demonstrated by the numerous clinical trials of new drugs with an expanding range of mechanisms of action and studies of optimal treatment strategies using currently available medications conducted worldwide. This review analyzes materials prepared by EULAR experts on the efficacy of current disease-modifying antirheumatic drugs and glucocorticoids in the treatment of RA.

  • Features of the disease-modifying antirheumatic drugs for rheumatoid arthritis in men depending on testosterone levels

    by T.S. Panevin, E.G. Zotkin, G.I. Gridneva, E.S. Matyushchenko, S.I. Glukhova

    Rheumatoid arthritis (RA) is associated with a high incidence of cardiovascular-kidney-metabolic conditions and hypogonadism syndrome in men. Objective. To study the features of antirheumatic therapy in men with rheumatoid arthritis and concomitant hypogonadism. Materials and methods. A total cross-sectional study including 169 men with a confirmed diagnosis of RA was carried out. Total testosterone level was measured in all patients; hypogonadism was diagnosed when the total testosterone level amounted to ≤12.0 nmol/L. A subgroup comparison of indicators reflecting the course and activity of RA, administered therapy and presence of concomitant diseases was performed in men with normal and reduced testosterone levels. Results. Patients with low testosterone level had similar RA duration, activity, and stage, but were less likely to receive methotrexate (26.8% versus 51.7%; p=0.006). Current duration of methotrexate administration or history of its intake was shorter in patients of the hypogonadism subgroup (1.0 [1.0; 3.0] year versus 3.0 [1.0; 7.0] years; p=0.027). In reduced testosterone level, a higher body mass index (31.0±4.0 kg/m2 and 26.1±3.7 kg/m2, respectively; p<0.001) and a higher incidence of obesity (63.7% compared to 10.6%; p<0.001) as well as diabetes mellitus (36.4% compared to 6.6%; p=0.004) were noted. The frequency and rate of application of other antirheumatic drugs were comparable, including the combination of methotrexate and genetically engineered biological therapy. Methotrexate withdrawal causes in the subgroups with normal and reduced testosterone levels did not differ statistically significantly. Nevertheless, a trend towards more frequent methotrexate discontinuation due to its poor tolerability was noted (26.8% compared to 14.1%; p=0.054) in patients of the group with reduced testosterone level. Conclusion. Hypogonadism in men with rheumatoid arthritis is associated with a higher incidence of comorbid metabolic disorders that contribute to methotrexate intolerance.

  • Transient constrictive pericarditis associated with COVID-19: a two-year follow-up and treatment

    by Z.N. Sukmarova, A.S. Starkova, E.G. Zotkin, A.M. Lila, M.N. Kabanova, E.R. Charchyan

    One of the most serious long-term consequences of the COVID-19 pandemic is constrictive pericarditis. This case demonstrates transient constriction in a young previously healthy woman. Transient nature of constrictive pericarditis was only thanks to extensive therapy and coordinated work of cardiac surgeon, cardiologist and rheumatologist. This case is typical in that it manifests a certain period after the main symptoms of the novel coronavirus infection. Constrictive pericarditis is suspected as the last in a series of multiple examinations. There were trivial changes in cardiac imaging, including standard echocardiography, up to the stage of anasarca. Interestingly, cardiac surgeons preferred therapeutic approach despite severe clinical status and multicomponent drug therapy for pericarditis including standard anti-inflammatory drugs (colchicine and nonsteroidal agents) and interleukin-1 inhibitors and human immunoglobulin. The last ones were previously unused In Russia for this purpose. Furthermore, the authors present a scheme of new echocardiographic parameters in the management of patients with constrictive pericarditis. This scheme was not previously used for decision-making in similar patients.